Hey there, bargain hunter. Not every great drug company announces a cancer moonshot this morning. Some just quietly convert modest top-line growth into outsized profit growth, raise their dividend, hold their guidance, and let the math do the talking. AstraZeneca did that today, October 30, 2026.
Scoreboard
AstraZeneca reported Q3 revenue of $16.209 billion, up 7% at constant exchange rates. The real number to hold onto is the profit line: core operating profit rose 20% to $5.855 billion, while core selling and administrative costs rose 2% and research spending 3%. Over nine months, core operating profit and core EPS each increased 14%, with nine-month core EPS reaching $8.00. The company also intends to increase the annual dividend to $3.30 per share.
What Actually Happened
The results surpassed Wall Street expectations; the average analyst estimate had been $2.60 in core EPS versus the $2.79 delivered. Revenue of $16.209 billion also beat the $16.09 billion Street forecast. None of this required a blockbuster surprise. It required discipline.
Oncology, now 48% of quarterly revenue, grew 17% to $7,765 million, led by Imfinzi up 26% and Enhertu up 35%. That franchise absorbed a genuine headwind: U.S. Farxiga sales fell 71% to $127 million year on year. The oncology engine covered the gap and then some.
The oncology arms race is not limited to approved drugs. Personalized mRNA cancer therapy has already posted a positive Phase 3 signal, opening a new competitive front for every oncology franchise.
The Business and How It Makes Money
AstraZeneca runs three main engines: oncology (47% of nine-month revenue), BioPharmaceuticals covering respiratory and cardiovascular, and rare disease. Double-digit growth in oncology, respiratory and immunology, and rare disease offset the Farxiga and Brilinta loss-of-exclusivity headwinds and volume-based procurement pressure in China. The mix shift toward higher-margin oncology is doing its work.
Key Metrics
- Q3 total revenue: $16,209 million, up 7% at constant exchange rates
- Core operating margin: 36%, up three percentage points year on year
- Core EPS: $2.79, up 19% at constant rates
- Gross margin: 82%, up one percentage point
- Other operating income: $277 million, including partner milestone payments and the disposal of Zoryve interest
- Net debt: $25.833 billion, up $2.459 billion since January 1
- FY2026 guidance reconfirmed: revenue mid-to-high single-digit growth, core EPS low double-digit growth, both at constant rates
Is It Cheap?
AZN currently trades at a forward P/E of about 15 times, and an enterprise value just under $293 billion. For context, nine-month core EPS is already $8.00 with a quarter left to run. The company is targeting $80 billion in total revenue by 2030 against roughly $63 billion expected this year. Eli Lilly trades around 40 times forward earnings. Johnson & Johnson, with slower growth and no comparable oncology pipeline depth, sits at a market cap above $650 billion. AZN at roughly $270 billion looks like the quiet cousin nobody invited.
Bull / Base / Bear
Bull: Enhertu and Imfinzi gain additional approvals, the rare disease segment sustains double-digit growth, and operating leverage pushes core margins toward 40% by 2028. The $80 billion 2030 revenue target becomes a floor.
Base: Revenue grows at mid-single digits. Cost discipline holds. Core EPS compounds at low double digits annually. The dividend rises steadily. Boring, consistent, and worth owning.
Bear: Net cash inflow from operating activities fell $1.343 billion over nine months, driven primarily by working capital changes, including the impact of Farxiga loss of exclusivity in the US, plus higher tax paid. If cash conversion continues to slip while net debt rises, that compounding story gets harder to trust. Add a major pipeline failure in oncology, and the multiple compresses fast.
Rising net debt is not automatically a red flag in this environment. Patent cliff pressure is forcing the largest acquisition wave in biopharma history, and balance sheets across the sector are being redeployed at scale.
Action Plan
AZN suits a patient, cost-conscious accumulator rather than a momentum trader. The stock has pulled back from its June highs. A scale-in across two or three tranches makes sense here: start a position at current levels, add on any broad market weakness, and size up if the Q4 results extend today’s margin trend. Hold, do not chase. Trim if net debt climbs another $3 billion without a corresponding rise in operating cash flow.
Cheap Investor Checklist
- Core operating margin at or above 36% next quarter: watch for it
- Oncology revenue above 45% of total sales: currently 48%, healthy
- Core EPS growth above 10% full-year at constant rates: on track
- Selling and admin cost growth below revenue growth: confirmed this quarter (2% vs 7%)
- Net debt below 1.5 times annual core operating profit: monitor closely
- Enhertu and Imfinzi combined quarterly revenue trend: watch for acceleration
- Forward P/E below 17 times: currently around 15, in range
- Annual dividend increase maintained: $3.30 confirmed
Bottom Line
If AstraZeneca can keep growing the top line at mid-to-high single digits while holding selling costs to low-single-digit increases, the profit math stays favorable for years. Today’s quarter proved that formula is working. The forward multiple is undemanding for a business with this kind of operating leverage and a pipeline that still has meaningful catalysts ahead. This is not a trade. It is a compounding machine priced like a utility.
